Zogenix (ZGNX) Chief Commercial Officer Scott Shively Departs

August 1, 2014 4:06 PM EDT

Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Scott Shively has resigned as Chief Commercial Officer in order to pursue another opportunity. In the interim, Roger Hawley, the Company's Chief Executive Officer, will assume the duties and responsibilities of the Chief Commercial Officer and lead the continued launch and commercial activities.

"Scott has laid a solid foundation for our expanded commercial team and we wish him success in his new endeavor," commented Roger Hawley, Chief Executive Officer. "Our experienced commercial team is already fully engaged in carrying out all planned activities and we expect continued growth without disruption. I look forward to leading the sales, marketing, managed care and trade teams to further direct focus to the commercial success of the Company."

Mr. Hawley, one of the co-founders of Zogenix, has extensive experience in leading commercial organizations with his prior experience at multiple pharmaceutical companies.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Hot Corp. News, Management Changes